Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.,Neuro-Oncology

当前位置： X-MOL 学术 › Neuro Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Neuro-Oncology ( IF 16.4 ) Pub Date : 2020-04-24 , DOI: 10.1093/neuonc/noaa106
Patrick Y Wen ₁ , Michael Weller ₂ , Eudocia Quant Lee ₁ , Brian M Alexander ₁ , Jill S Barnholtz-Sloan ₃ , Floris P Barthel ₄ , Tracy T Batchelor ₅ , Ranjit S Bindra ₆ , Susan M Chang ₇ , E Antonio Chiocca ₈ , Timothy F Cloughesy ₉ , John F DeGroot ₁₀ , Evanthia Galanis ₁₁ , Mark R Gilbert ₁₂ , Monika E Hegi ₁₃ , Craig Horbinski ₁₄ , Raymond Y Huang ₁₅ , Andrew B Lassman ₁₆ , Emilie Le Rhun ₁₇ , Michael Lim ₁₈ , Minesh P Mehta ₁₉ , Ingo K Mellinghoff ₂₀ , Giuseppe Minniti ₂₁ , David Nathanson ₂₂ , Michael Platten ₂₃ , Matthias Preusser ₂₄ , Patrick Roth ₂ , Marc Sanson ₂₅ , David Schiff ₂₆ , Susan C Short ₂₇ , Martin J B Taphoorn ₂₈ , Joerg-Christian Tonn ₂₉ , Jonathan Tsang ₂₂ , Roel G W Verhaak ₄ , Andreas von Deimling ₃₀ , Wolfgang Wick ₃₁ , Gelareh Zadeh ₃₂ , David A Reardon ₁ , Kenneth D Aldape ₃₃ , Martin J van den Bent ₃₄

Affiliation

Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA.
The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
Department of Neurology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School.
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA.
University of California San Francisco, San Francisco, California, USA.
Department of Neurosurgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
David Geffen School of Medicine, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mayo Clinic, Rochester, Minnesota, USA.
Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Division of Neuroradiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Department of Neurology and Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
University of Lille, Inserm, Neuro-oncology, General and Stereotaxic Neurosurgery service, University Hospital of Lille, Lille, France; Breast Cancer Department, Oscar Lambret Center, Lille, France and Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Miami Cancer Institute, Miami, Florida, USA.
Department of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Radiation Oncology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, USA.
Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany.
Division of Oncology, Department of Medicine, Medical University of Vienna, Vienna, Austria.
Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
University of Virginia School of Medicine, Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Department of Neurology, Medical Center Haaglanden, The Hague and Department of Neurology, Leiden University Medical Center, the Netherlands.
Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
Neuropathology and Clinical Cooperation Unit Neuropathology, University Heidelberg and German Cancer Center, Heidelberg, Germany.
Department of Neurology and Neuro-oncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, Toronto, Canada.
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.

中文翻译：

成人胶质母细胞瘤：神经肿瘤学会 (SNO) 和欧洲神经肿瘤学会 (EANO) 关于当前治疗和未来方向的共识审查。

胶质母细胞瘤是最常见的恶性原发性脑肿瘤，也是发病和死亡的重要原因。近年来，在了解这些肿瘤的分子发病机制和生物学方面取得了重要进展，但这并没有转化为患者预后的显着改善。在神经肿瘤学会 (SNO) 和欧洲神经肿瘤学会 (EANO) 的共识综述中，将讨论异柠檬酸脱氢酶野生型 ( IDH wt) 胶质母细胞瘤的当前治疗。此外，还将回顾靶向分子疗法、针对DNA损伤反应和代谢的药物、免疫疗法和病毒疗法等新型疗法，以及当前的挑战和未来的研究方向。

更新日期：2020-04-24

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11